ArticleFrontline gastroenterology2018
Evaluation of the clinical and cost-effectiveness of the York Faecal Calprotectin Care Pathway.
Article in Frontline gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparing outcomes from tailored meta-analysis with outcomes from a setting specific test accuracy study using routine data of faecal calprotectin testing for inflammatory bowel disease.BMC medical research methodology · 2022Pooled it
- Optimising triage of urgent referrals for suspected IBD: results from the Birmingham IBD inception study.Frontline gastroenterology · 2024Article
- Article
- Diagnostic value of fecal calprotectin in primary care patients with gastrointestinal symptoms: A retrospective Swedish cohort study.JGH open : an open access journal of gastroenterology and hepatology · 2023Article
- Review
- Faecal calprotectin testing in UK general practice: a retrospective cohort study using The Health Improvement Network database.The British journal of general practice : the journal of the Royal College of General Practitioners · 2021Article
- Article
- The Association of Introducing a Faecal Calprotectin Testing Pathway for Suspected Inflammatory Bowel Disease in Primary Care and Time to Diagnosis or Treatment.Inflammatory intestinal diseases · 2020Article
- Economic analysis of the adoption of capsule endoscopy within the British NHS.International journal for quality in health care : journal of the International Society for Quality in Health Care · 2020Article
- Rational investigations in irritable bowel syndrome.Frontline gastroenterology · 2020Article
- Getting the best out of faecal immunochemical tests and faecal calprotectin.Frontline gastroenterology · 2020Article
- Audit of the impact of the York faecal calprotectin care pathway on colonoscopy activity.Frontline gastroenterology · 2020Article
- Article
- Cost-effectiveness of faecal calprotectin used in primary care in the diagnosis of inflammatory bowel disease.BMJ open · 2019Article
- Evaluating the clinical and economic consequences of using video capsule endoscopy to monitor Crohn's disease.Clinical and experimental gastroenterology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the sensitivity and specificity of the York Faecal Calprotectin Care Pathway (YFCCP) and undertake a health economics analysis. The YFCCP has been introduced in support of the National Institute for Health and Care Excellence (NICE) guidance DG11. It is designed to improve the sensitivity and specificity of faecal calprotectin (FC) in discriminating the irritable bowel syndrome from inflammatory bowel disease in primary care.
designTo prospectively evaluate the clinical outcomes at 6 months of the first 1005 patients entering the YFCCP. To develop a cost-consequence model using two comparators: one based on clinical assessment and the C reactive protein/erythrocyte sedimentation rate without using FC, and the second using single testing of the standard FC cut-off.
settingNorth Yorkshire primary care practices. PATIENTS: Primary care patients fulfilling NICE DG11.
interventionsThe YFCCP.
main outcome measuresClinical outcome measures from secondary care records.
resultsThe sensitivity and specificity of the YFCCP are 0.94 (0.85 to 0.98) and 0.92 (0.90 to 0.94), giving a negative and positive predictive value of 0.99 (0.98 to 1.0) and 0.51 (0.43 to 0.59), respectively.
conclusionsThe YFCCP overcomes the challenges experienced with FC use in primary care, its efficacy matching initial NICE projections. It is readily incorporated into clinical practice. It should represent the framework on which to increase NICE DG11 implementation nationally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.